C4 Therapeutics, Inc.

C4 Therapeutics Inc. is a biotechnology company focused on developing targeted protein degradation therapies to treat a variety of diseases, primarily cancer. The company's core mission is to harness their proprietary technology, known as the TORPEDO platform, to create small molecule drugs that induce the degradation of disease-causing proteins. By eliminating these proteins, C4 Therapeutics aims to offer novel treatments with improved efficacy over traditional methods. The company's innovative approach impacts the healthcare sector, particularly within oncology, as well as potential applications in neurology and other disease areas. By focusing on protein degraders instead of conventional inhibitors, C4 Therapeutics is at the forefront of a significant shift in drug discovery and development processes. With a strong pipeline of therapeutic candidates in various stages of research and development, C4 Therapeutics plays a critical role in the biopharmaceutical landscape. Headquartered in Watertown, Massachusetts, the company collaborates with leading pharmaceutical firms to leverage its platform technology, underscoring its potential to influence future medical treatments and address unmet clinical needs.